Management of Hematologic Disorders

  • Author: David Aboulafia, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)


  • Anti-Rh antibody [drug: RHo D immune globulin] requires use of lower amounts of antibody than gamma globulin and is less costly, but there is risk of RBC hemolysis[Oksenhendler 1988; FDA Rho (D) Immune Globulin]
  • [drug: RHo D immune globulin] produces ~ 64% short-term response rate and more sustained platelet response than gamma globulin[Oksenhendler 1988]

Action required